Show simple item record

dc.creatorPang, Wentai
dc.creatorLiu, Zhi
dc.creatorLi, Nan
dc.creatorLi, Yuyun
dc.creatorYang, Fengwen
dc.creatorPang, Bo
dc.creatorJin, Xinyao
dc.creatorZheng, Wenke
dc.creatorZhang, Junhua
dc.date.accessioned2020-08-06T15:54:00Z
dc.date.available2020-08-06T15:54:00Z
dc.date.created2020-07-28
dc.identifier.issn2213-4220spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S2213422020301098?via%3Dihub#kwd0005spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11677
dc.format.extent29 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.publisherIntegrative Medicine Research
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectMedicina integralspa
dc.subjectDroga médica chinaspa
dc.subjectRevisión sistemáticaspa
dc.subjectConjunto de resultados básicosspa
dc.titleChinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysisspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.subject.keywordCoronavirus Disease 2019spa
dc.subject.keywordIntegrative medicinespa
dc.subject.keywordChinese medical drugspa
dc.subject.keywordSystematic reviewspa
dc.subject.keywordCore outcome setspa
dc.subject.keywordMeta analysisspa
dc.identifier.doihttps://doi.org/10.1016/j.imr.2020.100477spa
dc.description.abstractenglishBackground Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. Method A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. Result Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. Conclusion CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required. Keywords Coronavirus Disease 2019Integrative medicineChinese medical drugSystematic reviewCore outcome setMeta analysisspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record